Halozyme’s Enhanze drug delivery technology just won it a $105 million upfront payment from Bristol-Myers Squibb.
Halozyme’s Enhanze drug delivery technology just won it a $105 million upfront payment from Bristol-Myers Squibb, plus future milestones and royalties, under a deal covering up to 11 drugs. The deal covers cancer immunotherapy drugs, with the hope that Halozyme can help turn a 90-minute IV infusion into a simple injection. That hope is built on the company’s success with drugs like Herceptin and MabThera. And indeed, Roche has also expanded an existing partnership with Halozyme to cover an undisclosed target. -KT
